Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 4, 2007, Pages 637-646

  Sulowicz, Wladyslaw ^a   Locatelli, Francesco ^b   Ryckelynck, Jean Philippe ^c   Balla, Jozsef ^d   Csiky, Botond ^e   Harris, Kevin ^f   Ehrhard, Patricia ^g   Beyer, Ulrich ^g  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b A MANZONI HOSPITAL   (Italy)

^c CHU Clemenceau   (France)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e UNIVERSITY OF PÉCS   (Hungary)

^f LEICESTER GENERAL HOSPITAL   (United Kingdom)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR; ERYTHROPOIETIN; HEMOGLOBIN; MACROGOL DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; HUMAN; KIDNEY DISEASE; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANEMIA; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY DISEASES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL DIALYSIS;

EID: 34548207889     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03631006     Document Type: Article

References (43)

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1992). Arch Intern Med 162: 1401-1408, 2002
2. Hsu CY: Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens 11: 337-341, 2002
3. McClellan W, Aronoff SL, Bolton WK: The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20: 1501-1510, 2004
4. Evans RW, Rader B, Manninen DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263: 825-830, 1990
5. Barany P, Petterson E, Konarski-Svensson JK: Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant 8: 426-432, 1993
6. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8: 1921-1929, 1997
7. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999
8. Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N, Fivush B, Furth S: Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44: 1017-1023, 2004
9. Li S, Foley RN, Collins AJ: Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 65: 1864-1869, 2004
10. Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, Burrows-Hudson S, Messana JM, Levin N, Rajagopalan S, Port FK, Wolfe RA, Saran R: Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the renal research institute-CKD study. Am J Kidney Dis 45: 658-666, 2005
11. Barrett BJ, Fenton SS, Ferguson B, Halligan P, Langlois S, Mccready WG, Muirhead N, Weir RV: Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol 10[Suppl 13]: S292-S296, 1999
12. National Kidney Foundation: K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 27[Suppl 1]: S182-S238, 2001
13. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S, European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19[Suppl 2]: ii1-ii47, 2004
14. Pollock C, McMahon L: Haemoglobin. Nephrology 10[Suppl 4]: S108-Sl15, 2005
15. US Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005
16. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ: Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 121-132, 2004
17. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssolm DC, Held PJ, Port FK: Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 94-111, 2004
18. National Kidney Foundation: K/DOQI clinical practice guidelines: 2006 update. Am J Kidney Dis 47[Suppl 3]: S11-S145, 2006
19. Centers for Medicare & Medicaid Services. 2004 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality, Baltimore, December 2004
20. Locatelli F, Pisoni RL, Akizawa T, Cruz JM, DeOreo PB, Lanmeire NH, Held PJ: Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 44[Suppl 2]: 27-33, 2004
21. Lacson E Jr, Ofsthun N, Lazarus M: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41: 111-124, 2003
22. Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM: Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 46: 481-488, 2005
23. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68: 1337-1343, 2005
24. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191, 2006
25. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA: Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 87: S24-S31, 2003
26. El Nahas AM, Bello AK: Chronic kidney disease: The global challenge. Lancet 365: 331-340, 2005
27. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ: Darbepoetin alia administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19: 898-903, 2004
28. Disney A, de Jersey P, Kirkland G, Mantha M, Charlesworth J, Gallagher M, Harris D, Gock H, Mangos S, MacMillan J, Viswalingam A: Aranesp® (darbepoetin alfa) administered once monthly (QM) maintains hemoglobin (Hb) levels in chronic kidney disease (CKD) patients [Abstract]. Nephrol Dial Transplant 20[Suppl 5]: v254, 2005
29. Ling B, Walczyk M, Agarwal A, Carrol W, Lui W, Brenner R: Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 63: 327-334, 2005
30. Provenzano R, Bhaduri S, Singh AK; for the PROMPT Study Group: Extended epoetin alia dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clin Nephrol 2: 113-123, 2005
31. Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C: An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 260: 577-585, 2006
32. Macdougall IC: C.E.R.A. (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4: 436-440, 2005
33. Brandt M, Lanzendorfer M, Frische J, Haselbeck A, Jarsch M: Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells [Abstract]. Nephrol Dial Transplant 21[Suppl 4]: iv9, 2006
34. Dougherty FC, Reigner B, Jordan P, Pannier A: C.E.R.A. (continuous erythropoiesis receptor activator): Dose-response, pharmacokinetics and tolerability in Phase I multiple ascending dose studies [Abstract]. Proc Am Soc Clin Oncol 23: 603, 2004
35. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Regnier B: Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator in patients with chronic kidney disease. Clin J Am Soc Nephrol 1: 1211-1215, 2006
36. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA: Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50: 702-712, 1991
37. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392-2395, 1999
38. Locatelli F, Villa G, de Francisco ALM, Albertazzi A, Adrogue HJ, Dougherty FC, Beyer U; on behalf of the BA16286 Study Investigators: Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis. Curr Med Res Opin 23: 969-979, 2007
39. Besarab A, Moro O, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U: Efficacy and tolerability of intravenous C.E.R.A. in patients with CKD on dialysis previously treated with epoetin alfa: A randomized, open-label, 19-week, dose-finding study, with a 12-month extension phase. Clin Ther 26: 626-639, 2007
40. Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC; on behalf of the BA16528 Study Investigators: The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: Results of a phase II study. Clin Nephrol 67: 306-317, 2007
41. Levin NW, Fishbane S, Zeig S, Nassar G, Moran J, Villa G, Dougherty FC: Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [Abstract]. Nephrol Dial Transplant 21[Suppl 4]: iv117, 2006
42. Xue JL, Ma JZ, Louis TA, Collins AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 12: 2753-2758, 2001
43. Roderick P, Davies R, Jones C, Feest T, Smith S, Farrington K: Simulation model of renal replacement therapy: Predicting future demand in England. Nephrol Dial Transplant 19: 692-701, 2004